Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHVNNASDAQ:CNCENASDAQ:INDVNASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$15.82+0.9%$19.04$14.33▼$55.70$1.62B1.181.23 million shs1.64 million shsCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/AINDVIndivior$12.68+1.8%$10.61$7.33▼$18.50$1.75B0.981.06 million shs1.55 million shsSDGRSchrödinger$22.90+5.6%$22.78$16.60▼$28.47$1.68B1.84870,703 shs1.00 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven+1.33%+3.22%-30.48%-48.93%-54.26%CNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INDVIndivior+1.77%+7.28%+5.84%+26.67%-30.94%SDGRSchrödinger+5.58%+6.51%-9.45%+4.85%+6.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHVNBiohaven3.412 of 5 stars4.51.00.00.01.84.20.6CNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AINDVIndivior2.4982 of 5 stars2.63.00.00.02.11.71.9SDGRSchrödinger2.3054 of 5 stars3.51.00.00.02.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHVNBiohaven 3.07Buy$59.46275.79% UpsideCNCEConcert Pharmaceuticals 0.00N/AN/AN/AINDVIndivior 3.25Buy$15.0018.30% UpsideSDGRSchrödinger 3.00Buy$32.8043.23% UpsideCurrent Analyst Ratings BreakdownLatest CNCE, BHVN, SDGR, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025BHVNBiohavenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.005/13/2025BHVNBiohavenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025BHVNBiohavenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$61.00 ➝ $54.004/28/2025BHVNBiohavenRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $57.004/24/2025BHVNBiohavenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/16/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.003/20/2025BHVNBiohavenDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$60.003/7/2025BHVNBiohavenMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$69.00 ➝ $63.003/6/2025INDVIndiviorPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $13.003/5/2025BHVNBiohavenJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$72.00 ➝ $68.003/4/2025BHVNBiohavenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $54.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHVNBiohavenN/AN/AN/AN/A$5.34 per shareN/ACNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58INDVIndivior$1.17B1.49$2.57 per share4.94N/A∞SDGRSchrödinger$230.49M7.29$0.61 per share37.42$7.60 per share3.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHVNBiohaven-$408.17M-$9.36N/AN/AN/AN/A-225.12%-158.89%8/14/2025 (Estimated)CNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/AINDVIndivior$2M-$0.31N/A7.42N/A-3.96%-241.73%15.09%7/24/2025 (Estimated)SDGRSchrödinger$40.72M-$2.63N/AN/AN/A-91.84%-35.77%-24.51%7/30/2025 (Estimated)Latest CNCE, BHVN, SDGR, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025BHVNBiohaven-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A5/7/2025Q1 2025SDGRSchrödinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHVNBiohavenN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHVNBiohavenN/A2.892.89CNCEConcert PharmaceuticalsN/A9.039.03INDVIndiviorN/A0.830.65SDGRSchrödingerN/A4.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHVNBiohaven88.78%CNCEConcert Pharmaceuticals70.63%INDVIndivior60.33%SDGRSchrödinger79.05%Insider OwnershipCompanyInsider OwnershipBHVNBiohaven16.00%CNCEConcert Pharmaceuticals11.33%INDVIndiviorN/ASDGRSchrödinger8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHVNBiohaven239102.11 million84.94 millionOptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableINDVIndivior1,164137.88 millionN/ANot OptionableSDGRSchrödinger79073.38 million66.59 millionOptionableCNCE, BHVN, SDGR, and INDV HeadlinesRecent News About These CompaniesBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the InvestigationJune 3 at 10:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 3 at 9:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 2 at 1:16 PM | globenewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities InvestigationJune 2 at 10:00 AM | accessnewswire.comTwo Sigma Investments LP Acquires New Stake in Schrödinger, Inc. (NASDAQ:SDGR)June 2 at 4:06 AM | marketbeat.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the InvestigationJune 1 at 10:00 AM | accessnewswire.comSchrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and MarketingMay 30, 2025 | morningstar.comFraud Investigation Opened: Levi & Korsinsky Investigates Schrdinger, Inc. (SDGR) on Behalf of ShareholdersMay 30, 2025 | accessnewswire.comVoloridge Investment Management LLC Cuts Holdings in Schrödinger, Inc. (NASDAQ:SDGR)May 30, 2025 | marketbeat.comAmeriprise Financial Inc. Has $2.67 Million Position in Schrödinger, Inc. (NASDAQ:SDGR)May 30, 2025 | marketbeat.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial OfficerMay 29, 2025 | finance.yahoo.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial OfficerMay 29, 2025 | businesswire.comSchrdinger, Inc. (SDGR) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky TodayMay 29, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to ConnectMay 29, 2025 | accessnewswire.comOngoing Schrdinger, Inc. (SDGR) Investigation: Protect Your Rights - Contact Levi & KorsinskyMay 28, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities InvestigationMay 28, 2025 | accessnewswire.comIntegrated Advisors Network LLC Sells 17,547 Shares of Schrödinger, Inc. (NASDAQ:SDGR)May 28, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $31.25 Million Stock Holdings in Schrödinger, Inc. (NASDAQ:SDGR)May 28, 2025 | marketbeat.comBNP Paribas Financial Markets Makes New Investment in Schrödinger, Inc. (NASDAQ:SDGR)May 28, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRMay 27, 2025 | accessnewswire.comRXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?May 27, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNCE, BHVN, SDGR, and INDV Company DescriptionsBiohaven NYSE:BHVN$15.82 +0.14 (+0.91%) Closing price 06/3/2025 03:59 PM EasternExtended Trading$16.00 +0.17 (+1.09%) As of 06/3/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Concert Pharmaceuticals NASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.Indivior NASDAQ:INDV$12.68 +0.22 (+1.77%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$12.68 0.00 (-0.04%) As of 06/3/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Schrödinger NASDAQ:SDGR$22.90 +1.21 (+5.58%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$22.37 -0.53 (-2.31%) As of 06/3/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
